These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 25767435)

  • 1. Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.
    Wang H; Pati S; Pozzo-Miller L; Doering LC
    Front Cell Neurosci; 2015; 9():55. PubMed ID: 25767435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.
    Gürkan CK; Hagerman RJ
    Res Autism Spectr Disord; 2012 Oct; 6(4):1311-1320. PubMed ID: 23162607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways to drug development for autism spectrum disorders.
    Hampson DR; Gholizadeh S; Pacey LK
    Clin Pharmacol Ther; 2012 Feb; 91(2):189-200. PubMed ID: 22205199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autism Spectrum Disorders and Drug Addiction: Common Pathways, Common Molecules, Distinct Disorders?
    Rothwell PE
    Front Neurosci; 2016; 10():20. PubMed ID: 26903789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders.
    Theoharides TC; Athanassiou M; Panagiotidou S; Doyle R
    J Neuroimmunol; 2015 Feb; 279():33-8. PubMed ID: 25669997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Human Neuronal Protein Complexes Reveals Biochemical Activities and Convergent Mechanisms of Action in Autism Spectrum Disorders.
    Li J; Ma Z; Shi M; Malty RH; Aoki H; Minic Z; Phanse S; Jin K; Wall DP; Zhang Z; Urban AE; Hallmayer J; Babu M; Snyder M
    Cell Syst; 2015 Nov; 1(5):361-374. PubMed ID: 26949739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and therapeutic challenges in autism spectrum disorders: insights from Rett syndrome.
    Castro J; Mellios N; Sur M
    Curr Opin Neurol; 2013 Apr; 26(2):154-9. PubMed ID: 23449173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.
    Spooren W; Lindemann L; Ghosh A; Santarelli L
    Trends Pharmacol Sci; 2012 Dec; 33(12):669-84. PubMed ID: 23084458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetics of autism.
    Muhle R; Trentacoste SV; Rapin I
    Pediatrics; 2004 May; 113(5):e472-86. PubMed ID: 15121991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of reduced expression of fragile X mental retardation protein in neurons and increased expression in astrocytes in idiopathic and syndromic autism (duplications 15q11.2-q13).
    Wegiel J; Brown WT; La Fauci G; Adayev T; Kascsak R; Kascsak R; Flory M; Kaczmarski W; Kuchna I; Nowicki K; Martinez-Cerdeno V; Wisniewski T; Wegiel J
    Autism Res; 2018 Oct; 11(10):1316-1331. PubMed ID: 30107092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging pharmacological therapies in fragile X syndrome and autism.
    Yamasue H; Aran A; Berry-Kravis E
    Curr Opin Neurol; 2019 Aug; 32(4):635-640. PubMed ID: 31045620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome.
    Valenti D; de Bari L; De Filippis B; Henrion-Caude A; Vacca RA
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():202-17. PubMed ID: 24548784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autism spectrum disorders: emerging mechanisms and mechanism-based treatment.
    Wang H; Doering LC
    Front Cell Neurosci; 2015; 9():183. PubMed ID: 26029053
    [No Abstract]   [Full Text] [Related]  

  • 14. Autism and fragile X syndrome.
    Yu TW; Berry-Kravis E
    Semin Neurol; 2014 Jul; 34(3):258-65. PubMed ID: 25192504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABA system dysfunction in autism and related disorders: from synapse to symptoms.
    Coghlan S; Horder J; Inkster B; Mendez MA; Murphy DG; Nutt DJ
    Neurosci Biobehav Rev; 2012 Oct; 36(9):2044-55. PubMed ID: 22841562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.
    Tsiouris JA; Brown WT
    CNS Drugs; 2004; 18(11):687-703. PubMed ID: 15330685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA and its contribution to autism spectrum disorders.
    Tang J; Yu Y; Yang W
    CNS Neurosci Ther; 2017 Aug; 23(8):645-656. PubMed ID: 28635106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive deficits in Rett syndrome: what we know and what we need to know to treat them.
    Berger-Sweeney J
    Neurobiol Learn Mem; 2011 Nov; 96(4):637-46. PubMed ID: 21624480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Synaptic Dysregulation in Fragile X Syndrome and Autism Spectrum Disorders.
    Telias M
    Front Mol Neurosci; 2019; 12():51. PubMed ID: 30899214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autism Spectrum Disorders: Multiple Routes to, and Multiple Consequences of, Abnormal Synaptic Function and Connectivity.
    Carroll L; Braeutigam S; Dawes JM; Krsnik Z; Kostovic I; Coutinho E; Dewing JM; Horton CA; Gomez-Nicola D; Menassa DA
    Neuroscientist; 2021 Feb; 27(1):10-29. PubMed ID: 32441222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.